Bajema Kristina L, Dahl Rebecca M, Prill Mila M, Meites Elissa, Rodriguez-Barradas Maria C, Marconi Vincent C, Beenhouwer David O, Brown Sheldon T, Holodniy Mark, Lucero-Obusan Cynthia, Rivera-Dominguez Gilberto, Morones Rosalba Gomez, Whitmire Alexis, Goldin Evan B, Evener Steve L, Tremarelli Maraia, Tong Suxiang, Hall Aron J, Schrag Stephanie J, McMorrow Meredith, Kobayashi Miwako, Verani Jennifer R, Surie Diya
MMWR Morb Mortal Wkly Rep. 2021 Sep 17;70(37):1294-1299. doi: 10.15585/mmwr.mm7037e3.
COVID-19 mRNA vaccines (Pfizer-BioNTech and Moderna) have been shown to be highly protective against COVID-19-associated hospitalizations (1-3). Data are limited on the level of protection against hospitalization among disproportionately affected populations in the United States, particularly during periods in which the B.1.617.2 (Delta) variant of SARS-CoV-2, the virus that causes COVID-19, predominates (2). U.S. veterans are older, more racially diverse, and have higher prevalences of underlying medical conditions than persons in the general U.S. population (2,4). CDC assessed the effectiveness of mRNA vaccines against COVID-19-associated hospitalization among 1,175 U.S. veterans aged ≥18 years hospitalized at five Veterans Affairs Medical Centers (VAMCs) during February 1-August 6, 2021. Among these hospitalized persons, 1,093 (93.0%) were men, the median age was 68 years, 574 (48.9%) were non-Hispanic Black (Black), 475 were non-Hispanic White (White), and 522 (44.4%) had a Charlson comorbidity index score of ≥3 (5). Overall adjusted vaccine effectiveness against COVID-19-associated hospitalization was 86.8% (95% confidence interval [CI] = 80.4%-91.1%) and was similar before (February 1-June 30) and during (July 1-August 6) SARS-CoV-2 Delta variant predominance (84.1% versus 89.3%, respectively). Vaccine effectiveness was 79.8% (95% CI = 67.7%-87.4%) among adults aged ≥65 years and 95.1% (95% CI = 89.1%-97.8%) among those aged 18-64 years. COVID-19 mRNA vaccines are highly effective in preventing COVID-19-associated hospitalization in this older, racially diverse population of predominately male U.S. veterans. Additional evaluations of vaccine effectiveness among various age groups are warranted. To prevent COVID-19-related hospitalizations, all eligible persons should receive COVID-19 vaccination.
2019冠状病毒病（COVID-19）信使核糖核酸（mRNA）疫苗（辉瑞-生物新技术公司和莫德纳公司生产）已被证明对预防COVID-19相关住院具有高度保护作用（1-3）。在美国，受影响 disproportionately 的人群中，针对住院的保护水平数据有限，尤其是在导致COVID-19的严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的B.1.617.2（德尔塔）变异株占主导的时期（2）。与美国普通人群相比，美国退伍军人年龄更大、种族更多样化，且潜在医疗状况的患病率更高（2,4）。美国疾病控制与预防中心（CDC）评估了mRNA疫苗在2021年2月1日至8月6日期间，对在五家退伍军人事务医疗中心（VAMC）住院的1175名年龄≥18岁的美国退伍军人中预防COVID-19相关住院的有效性。在这些住院患者中，1093人（93.0%）为男性，年龄中位数为68岁，574人（48.9%）为非西班牙裔黑人（黑人），475人为非西班牙裔白人（白人），522人（44.4%）的查尔森合并症指数评分≥3（5）。针对COVID-19相关住院的总体调整后疫苗有效性为86.8%（95%置信区间[CI]=80.4%-91.1%），在SARS-CoV-2德尔塔变异株占主导之前（2月1日至6月30日）和期间（7月1日至8月6日）相似（分别为84.1%和89.3%）。≥65岁成年人的疫苗有效性为79.8%（95%CI=67.7%-87.4%），18-64岁成年人的疫苗有效性为95.1%（95%CI=89.1%-97.8%）。COVID-19 mRNA疫苗在预防这一以男性为主、年龄较大且种族多样的美国退伍军人人群中与COVID-19相关的住院方面非常有效。有必要对不同年龄组的疫苗有效性进行进一步评估。为预防与COVID-19相关的住院，所有符合条件的人都应接种COVID-19疫苗。
